Building on complementary mechanisms between cancer and fibrosis

Our Pipeline

iOnctura’s pipeline contains an exquisitely selective PI3Kδ small molecule inhibitor which has just entered a phase I clinical trial in solid tumours, a second generation selective ATX small molecule inhibitor that is in IND enabling studies and an early preclinical phase anti-CD73 antibody program.

our current projects

Pipeline

–

WHO WE ARE

Catherine Pickering, CEO

Catherine holds a PhD in Medicinal Chemistry from The Institute of Cancer Research, London and an MBA from Henley Management College, UK. She is an experienced deal maker with broad transaction experience including licensing (in- and out licensing, option deals, and strategic collaborations) and M&A.

Lars van der Veen, COO

Lars holds a PhD in homogeneous catalysis (cum laude) from the University of Amsterdam. He is an experienced project and alliance manager with demonstrated leadership in pre-clinical and clinical development. He has managed >25 alliances for in-licensed and out-licensed products of both biologics and small molecules, driving governance, delivery of results and issue resolution.

Zoë Johnson,
CSO

Zoë holds a PhD in Pharmacology from King's College London, UK. Zoë has more than 15 years of experience in the biopharmaceutical industry in the UK and Europe where she has worked across a range of therapy areas including oncology, autoimmune & inflammatory diseases and allergy.

Michael Lahn, CMO

Michael holds a MD in Medical Microbiology from the University of Mainz. He has over 20 years’ experience in oncology clinical development in the pharmaceutical industry, where he was responsible for the development of multiple molecules through early and late clinical development.

MEET THE TEAM

iOnctura in the news: Emerging Company Profile by Scrip Informa Pharma Intelligence

iOnctura Develops Next-Generation PI3K-Delta Inhibitors For Cancer Executive Summary Emerging Company Profile: Switzerland’s iOnctura is working on PI3K-delta inhibitors and autotaxin inhibitors that have potential in solid tumors and cancer-associated fibrosis. The European start-up iOnctura SA is developing candidate products with immuno-oncologic and direct anti-tumor properties, and has just dosed its first patient in a … Continue reading “iOnctura in the news: Emerging Company Profile by Scrip Informa Pharma Intelligence”

iOnctura announces first patient dosed in a phase I clinical study of its novel highly selective PI3Kδ inhibitor, IOA-244 for solid tumours

Geneva, Switzerland, 26 February 2020: iOnctura SA., a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, announces it has dosed the first patient in a first-in-human dose escalation and expansion study evaluating the safety and preliminary efficacy of its lead programme IOA-244, which is being developed as a … Continue reading “iOnctura announces first patient dosed in a phase I clinical study of its novel highly selective PI3Kδ inhibitor, IOA-244 for solid tumours”